Introduction
Diabetic nephropathy is the most common single cause of end-stage renal disease in the USA, and affects patients with both type 1 and type 2 diabetes [1] . Mesangial matrix expansion and glomerular basement membrane thickening have been recognized as the key histological features of diabetic nephropathy [2] . However, loss of podocyte structure and function has been described as one of the early features of diabetic nephropathy in both patients with type 1 and those with type 2 diabetes [3-10], and represents an independent predictor of disease progression in patients at high risk for diabetic nephropathy [4, 5] . Loss of podocyte number has also been described in experimental models of diabetic nephropathy [11, 12] . In these models, podocytopenia is independent of the hemodynamic derangement that characterizes diabetic nephropathy including significant increases in blood pressure, suggesting an important role of glucose metabolism in the loss of podocyte structure and function [13] .
The notion that deranged glucose metabolism plays a pivotal role in podocyte malfunction has advanced but remains to be established. Although the primary defect in type 1 diabetes is diminished insulin secretion and in type 2 diabetes is diminished insulin sensitivity, it is widely recognized that insulin resistance occurs in type 1 diabetes [14, 15] and that beta cell failure develops in type 2 diabetes [16] [17] [18] . Apart from the traditional target organs of insulin action (liver and skeletal muscle), the cardiovascular system and the kidney have been also recognized to be insulin targets [19] . Although insulin resistance may certainly play a role in the timing of the clinical onset of type 1 and 2 diabetes, it also may affect both microvascular and macrovascular outcomes of diabetes [20] . Thus, it is possible that disruption of normal insulin signaling (hyperinsulinemia, insulin resistance or absolute insulin deficiency) may play a significant role in the pathogenesis of diabetic complications. We will review herein the clinical and experimental evidence linking insulin resistance and/or hyperinsulinemia to diabetic nephropathy. We will particularly focus attention on experimental studies aimed at the analysis of the effect of insulin and insulin signaling on podocyte function.
Insulin resistance and microalbuminuria
Microalbuminuria is the earliest clinical manifestation of diabetic nephropathy [21] and represents a major risk for cardiovascular events and for progression to end-stage renal disease [21] [22] [23] . Multiple studies have shown that insulin resistance correlates with the onset of microalbuminuria in patients with type 2 diabetes and their siblings [18, 20, 24, 25] , as well as in nondiabetic individuals [26] . Interestingly, the correlation between insulin resistance and microalbuminuria is independent of blood pressure, since it has been reported also in normotensive patients with type 2 diabetes [20] . Impaired insulin sensitivity in diabetic patients may be associated with altered renal cell glucose metabolism, contributing to progressive disease independent of hyperglycemia [25] . The correlation of microalbuminuria with insulin resistance in normotensive and normoglycemic patients suggests that insulin resistance alone may have a causative role in the development of microalbuminuria.
Diabetic nephropathy develops with similar features in type 1 and type 2 diabetes [2]. Since insulin resistance is associated with microalbuminuria in type 2 diabetes, the question arises of how insulin resistance may contribute to diabetic nephropathy in type 1 diabetes. Insulin resistance has indeed been reported in type 1 diabetes [14, 15, 25] . The EUROPDIAB study, which analyzed 1134 normotensive patients with type 1 diabetes, has clearly shown that surrogate markers of insulin resistance (such as elevated tryglycerides and increased waist-to-hip ratio) are risk factors for the development of microalbuminuria [27] . Insulin resistance has indeed been shown to precede microalbuminuria in 16 uncomplicated patients with type 1 diabetes [28] . Seven out of those 16 patients developed microalbuminuria at 3 years of follow-up, and development of microalbuminuria was associated with significantly lower glucose disposal rate (P < 0.01) than those patients without microalbuminuria. In a separate study, the total body glucose disposal rate was compared in 14 patients with type 1 diabetes and normoalbuminuria and 14 patients with microalbuminuria. A lower glucose disposal rate reflective of insulin resistance was observed in patients with microalbuminuria [29] . A similar correlation between insulin resistance and microalbuminuria was reported in euglycemic family members of type 1 diabetic patients with microalbuminuria [30] . However, one study comparing normoalbuminuric and microalbuminuric patients failed to identify a correlation between insulin resistance and microalbuminuria [31] . Supporting a correlation between insulin resistance and the development of microvascular complications are experimental data on diabetic retinopathy. In fact, insulin-receptor signaling is highly compromised in the retina of a model of streptozotocin-induced diabetes in rats, suggesting that a disrupted insulin-signaling pathway may play a key role in the development of microvascular complications of diabetes [32] . Furthermore, renal disease similar to diabetic nephropathy can be observed in patients with a genetic mutation of the insulin receptor, which would again suggest that disruption of normal insulin signaling is a part of the disease process in diabetic nephropathy [33] .
Hyperinsulinemia and microalbuminuria
Hyperinsulinemia is often utilized as a surrogate marker of insulin resistance. However, there is not sufficient evidence to distinguish whether insulin resistance or hyperinsulinemia is the significant risk factor for the development of microalbuminuria. A summary of relevant studies that have investigated an association of insulin resistance or hyperinsulinemia with microalbuminuria is provided in Table 1 . Such an important gap of knowledge requires further investigation, since it may strongly influence the decision to utilize insulin sensitizers and/or insulin in a different manner, particularly in those patients at risk for the development of microalbuminuria. An elegant study performed in 1980 showed that insulin infusion during euglycemic clamps in patients with type 1 diabetes resulted in the development of transient albuminuria 45 min after initiation of insulin infusion [19] . A recent report in 175 patients with type 1 diabetes from the Natural History of Diabetes Study has shown correlation between microalbuminuria and fasting insulin but not microalbuminuria and insulin resistance [34] . The role of hyperinsulinemia alone as a risk factor for microalbuminuria has been studied in type 2 diabetes as well [35, 36] . It is interesting to note that insulin can influence glomerular permeability to albumin in patients with type 2 diabetes but not in healthy individuals [35] , suggesting that a disruption of the insulin signaling cascade may be sufficient for insulin to result in microalbuminuria in type 2 diabetes.
Renoprotective effects of insulin sensitizers in diabetes
Whether hyperinsulinemia and/or insulin resistance play a causative role in the development of microalbuminuria can be addressed by the analysis of renal outcomes in intervention trials aimed at the improvement of insulin resistance, particularly those trials designed to compare the effect of insulin sensitizers with other hypoglycemic agents and or insulin. A recent double-blind, randomized, placebo-controlled study examined the change in urinary albumin excretion (UAE), the improvement in insulin sensitivity and circulating adipocytokine levels in patients with type 2 diabetes mellitus treated with rosiglitazone when compared with other oral hypoglycemic patients. Despite a similar hemoglobin A1c (A1c), patients receiving rosiglitazone had a significant reduction in UAE at 3 months of follow-up. Such a reduction was associated with increased adiponectin concentrations [37] . This is interesting, since, among the multiple pleiotropic functions of adiponectin, a direct role in the prevention of proteinuria and podocyte damage has been recently recognized in experimental animals [38] . Another multicentered randomized controlled trial compared the effect of metformin and pioglitazone in 1200 patients with type 2 diabetes. After 52 weeks of treatment, patients had equal A1c and fasting plasma glucose. However, patients randomized to pioglitazone had an 18% reduction in the albumin/creatinine ratio compared with 2% in the metformin-treated group [39] . Those trials indeed suggest that the agent used to achieve a target A1c may have a highly significant impact on renal outcome. If fact, a posthoc analysis of the UKPDS trial focusing on 1704 overweight patients (UKPDS 34) was designed to investigate whether intensive glucose control with metformin had any specific advantage or disadvantage [40] . Among patients randomized to intensive blood-glucose control, metformin, which enhances insulin sensitivity, also showed a greater effect than chlorpropamide, glibenclamide, or insulin for any diabetes-related endpoint, including albuminuria.
A potential causative role of insulin in the development of microalbuminuria is suggested by insulin infusion studies in type 1 diabetic patients [19] as well as in a very provocative cross-sectional study in 890 patients with type 2 diabetes. In the latter, patients receiving insulin versus other hypoglycemic agents were compared [41] . After correction for diabetes duration, sex, and A1c, those patients treated with insulin had a higher incidence of microalbuminuria [41] . Thus, studies specifically designed to address whether insulin per se may be deleterious to renal outcome are needed. These findings, combined with the recently reported increased cardiovascular mortality in 10 251 patients with type 2 diabetes receiving intensive treatment for diabetes (mainly with insulin) [42] , offer a strong rationale to compare outcomes when different hypoglycemic agents are utilized.
Although large clinical trials of the thiazolidinediones (TZDs) have been curtailed due to the increased cardiovascular mortality reported with rosiglitazone [43] , a post-hoc analysis of the PROactive trial performed in a selected population of patients with type 2 diabetes and glomerular filtration rate less than 60 ml/min has demonstrated that pioglitazone utilization is well tolerated in this patient population and that it may even confer protection from major cardiovascular events [44] .
Among experimental studies supporting a favorable role of insulin sensitizers versus insulin in renoprotection, Ohtomo et al. [45 ] randomized diabetic rats to receive either pioglitazone (PGZ) or insulin. This study demonstrated that PGZ but not insulin reduced proteinuria, preserved renal function, and improved diabetic glomerular and tubular lesions. This effect was independent of the metabolic control, since fasting glycemia and A1C were improved but more so with insulin than with PGZ [45 ] . Furthermore, very provocative experimental data do exist suggesting a role for peroxisome-proliferatorreceptor-(PPR)-alpha agonists in the improvement of insulin resistance and albuminuria [46] . Fenofibrates act as PPAR-alpha ligands and improve insulin sensitivity and glycemic control. In the kidney, fenofibrates decreased UAE and attenuated glomerular mesangial matrix accumulation in db/db mice, a known model of type 2 diabetes [46] . Whether any means to improve peripheral insulin sensitivity may translate into prevention of diabetic nephropathy remains to be established. Whereas aspirin has been recognized to have insulinsensitizing properties [47] , no data have suggested so far that it can improve UAE in either type 2 [48] or type 1 diabetic patients [49] . In addition, we have recently reported that db/db mice treated with a JNK inhibitor as well as JNK knock-out mice rendered diabetic by streptozotocin injection (STZ) experience improved insulin sensitivity concomitant with worsened albuminuria [50 ] . Thus, not all insulin-sensitizing agents may be renoprotective.
Podocytes and insulin signaling
The glomerular filtration barrier has three important components: endothelial cells, the glomerular basement membrane and the podocytes [51] . Recently, the role of podocytes in diabetic nephropathy has become the subject of intense research effort, since podocyte foot process effacement and decreased podocyte number have been reported in patients with either type 1 or type 2 diabetes in the early phases of diabetic nephropathy [3,5-10,52].
Podocytes express all the elements of the insulin signaling cascade as well as glucose transporters such as GLUT-1 and GLUT-4 [53] , and are capable of increasing their glucose uptake when they are stimulated with insulin. Furthermore, we have recently demonstrated that podocytes isolated from diabetic db/db mice are unable to respond to insulin even when isolated from mice prior to the onset of microalbuminuria [54] . However, the role of insulin signaling as well as the molecular mechanisms of podocyte-specific insulin resistance remains to be established. One possibility is that the local inflammatory phenotype associated with insulin resistance may contribute to podocyte malfunction. This is suggested by experimental intervention studies that have demonstrated how TZDs may ameliorate the progression of podocyte injury associated with puromucin aminonucleoside, a model to evaluate renal injury in rats [55] . In fact, TZDs directly affect the secretion of proinflammatory mediators by macrophages (macrophage colony stimulated factor, tumor necrosis factor-a, interleukin-6, PAI-1 and interleukin-1b) and modulate podocyte apoptosis (decreased activated caspase 3, restoration of p27 and Bcl-xl) [55] . Thus, a potential role for TZDs as a therapeutic strategy in podocyte-related diseases is warranted [56] . Among other potential mechanisms of podocyte-specific insulin resistance, we have shown that podocyte inability to respond to insulin may result from an increased phosphorylation of c-jun N terminal kinase (JNK) [50 ] , a mediator of inflammation, apoptosis and insulin resistance. JNK activation resulted in increased susceptibility to cell death through the inability to properly phosphorylate AKT [54] . However, as discussed earlier, whereas treatment of db/db mice with JNK inhibitors resulted in improved peripheral insulin sensitivity, worsening of albuminuria was also observed [50 ] . Interestingly, JNK inhibition resulted in a downregulation of nephrin mRNA in both db/þ and db/db glomeruli [50 ] . Nephrin is a transmembrane protein of the inmunoglobulin superfamily; mutations of the genes that code for this protein cause a severe proteinuric syndrome in children with congenital nephrotic syn-drome of the Finnish type [57] . Nephrin is thought to prevent protein loss through the maintenance of the slit diaphragm between adjacent podocyte foot processes, serving as a signal molecule and regulating the actin cytoskeleton of the podocyte through Nck adaptor proteins [58] [59] [60] , which could in turn affect proper trafficking of receptors and glucose transporter to the cell membrane. In fact, nephrin is essential to allow insulindependent GLUT-4 vesicle translocation to the plasma membrane in podocytes [61 ] , and regulation of nephrin expression in the early phases of diabetic nephropathy has been described [62] . Thus, the potential role of nephrin in the development of podocyte-specific insulin resistance should also be further investigated. Among other potential mechanisms to be explored, the modulation of adiponectin production observed in diabetes may also directly affect podocyte function [38] . Although it has been demonstrated that adiponectin protects podocytes via stimulation of the AMPK pathway and reduced oxidative stress, it is also possible that adiponectin facilitates proper glucose uptake in podocytes as described in other peripheral tissues [63] . Furthermore, adiponectin resistance may occur in podocytes and contribute to cell malfunction; in this respect, we have generated preliminary data suggesting a down-regulation of adiponectin receptors 1 and 2 in podocytes isolated from db/db mice when compared with db/þ (data not shown). The role of cathepsin L in the development of podocyte insulin resistance should also be considered. Cathepsin L has been shown to be markedly up-regulated in diabetic glomeruli [64] , and increased cathepsin L is associated with degradation of insulin receptor b subunits and GLUT-4 in adipocytes [65] . Thus, it is possible that podocyte-specific insulin resistance is related to a modulation of cathepsin L expression and function in podocytes. A graphic representation of the altered metabolic function that may occur in podocytes exposed to a diabetic environment is shown in (Fig. 1) .
One additional possibility is that insulin per se, particularly in the setting of compromised insulin receptor signaling, may signal through alternative pathways and be deleterious to podocyte function. It is possible, for instance, that insulin directly affects in a PI3K/PIP3dependent manner the activity of transient receptor potential canonical channel 6 (TRPC6) [66] , which have been demonstrated to play an important role in several proteinuric diseases [67] [68] [69] . This is particularly important, since calcium influx and calcineurin activation in podocytes have been characterized as key determinants of podocyte function [70, 71] and calcineurin isoforms are up-regulated in the experimental diabetic nephropathy [72] . Furthermore, since we have demonstrated podocyte-specific insulin resistance in early diabetes [54] , and our prior observations demonstrated a strong autocrine up-regulation of the IGF-1 receptor pathway in experimental models of diabetic nephropathy [73] [74] [75] , it is possible that insulin, in the presence of insulin resistance, acts through alternative pathways, such as the IGF-1 pathway, that we have shown to be deleterious to glomerular cells [73] [74] [75] .
Summary and conclusion
In summary, several studies have suggested a contribution of insulin resistance and hyperinsulinemia to the development of microalbuminuria. Clinical and experimental studies have also suggested that improvement of insulin resistance in diabetes may result in improvement of albuminuria. Whether this translates into improvement of glomerular filtration rate and decreased progression to end-stage renal disease remains to be established. Whereas long-term follow-up studies are being performed to address this latter question, understanding the direct role of insulin and insulin receptor signaling in podocytes may lead to the development of novel therapeutic strategies for the prevention and the cure of diabetic nephropathy. Shown is a schematic and simplified representation of glucose metabolism in normal and diabetic podocytes. In NORMAL PODOCYTES, glucose uptake is granted by normal insulin receptor signaling and glucose transporter expression and function (mainly GLUT-4). GLUT4 is kept functional by proper nephrin expression and GLUT-4 vesicle trafficking to the plasma membrane. Furthermore, adiponectin may contribute to normal glucose uptake via AMPK. Normal insulin and adiponectin signaling will facilitate cell survival through proper phosphorylation of AKT. In the DIABETIC PODOCYTE, the local inflammatory stress may lead to disruption of insulin receptor signaling via reactive oxygen species generation and activation of stress-activated protein kinases such as NF-kB and JNK, responsible for cell malfunction and cell death. Furthermore, suppression of nephrin expression and decreased adiponectin signaling will result in GLUT-4 intracytoplasmic sequestration and lack of function, whereas up-regulation of cathepsin L may contribute to degradation of insulin receptor and GLUT-4. Solid line, stimulation; dotted line, inhibition.
